ORPHA:703
Bullous pemphigoid
Publications
11,151
97.9th percentile
Trials
36
Interventional, condition-specific
Researchers
998
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare autoimmune bullous skin disease characterized by acquired, subepidermal tense bullae occurring on normal of inflamed skin and that is typically widespread (occurring in the flexor regions of the proximal arms and legs, in the armpits, groin and the abdomen) and often associated with pruritus. The evolution is typically chronic with spontaneous exacerbations and remission.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019082
- MeSH:D010391
- UMLS:C0030805
- NCIT:C84389
Additional Mondo synonyms (1)
bullous pemphigoid
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
11,151 matched papers (6,161 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
36 matched on ClinicalTrials.gov (3 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
11,151
11,151 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
11,151 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
6,161 in the last 10 years · high confidence · 97.9th percentile (publications denominator)
Phrase hits: 11,151 · MeSH hits: 0
Who's working on it?
998
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang Y10 papers · 2026
Department of Dermatology, The National Center for the Integration of Traditional Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.
Papers in Europe PMC - 02Zhang J8 papers · 2026
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Papers in Europe PMC - 03Antiga E6 papers · 2026
Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
Papers in Europe PMC - 04Li J6 papers · 2026
Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China.
Papers in Europe PMC - 05Liu Y6 papers · 2026
Department of Hepatology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, People's Republic of China.
Papers in Europe PMC - 06Maglie R6 papers · 2026
Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
Papers in Europe PMC - 07Li L5 papers · 2026
The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
Papers in Europe PMC - 08Li W5 papers · 2026
Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China.
Papers in Europe PMC - 09Amber KT4 papers · 2026
Department of Dermatology, Rush University Medical Center, Chicago, Illinois, USA.
Papers in Europe PMC - 10Baffa ME4 papers · 2026
Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
36
interventional trials for this specific condition
36 interventional trials matched this specific condition name; 3 currently recruiting in our sample.
Data as of 27 July 2026
36 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 96.1th percentile).
high confidence · 96.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
36 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07210554·NOT YET RECRUITING·Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid
Conditions: Bullous Pemphigoid (BP)·Matched via name phrase
- NCT06371417·RECRUITING·Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Conditions: Antiphospholipid Syndrome (APS) · Bullous Pemphigoid (BP) · Behçet's Syndrome (BS) · Dermatomyositis (DM)·Matched via name phrase
- NCT06723106·ENROLLING BY INVITATION·Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Conditions: Antiphospholipid Syndrome (APS) · Bullous Pemphigoid (BP) · Behçet's Syndrome (BS) · Dermatomyositis (DM)·Matched via name phrase
Observational and natural-history studies
20 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05366127·NOT YET RECRUITING·Validation of a Simplified Severity Score (Investigator Global Assessment: IGA) in Bullous Pemphigoid
Conditions: Bullous Pemphigoid·Matched via name phrase
- NCT02753777·RECRUITING·Autoimmune Blistering Diseases Study
Conditions: Pemphigus Vulgaris · Pemphigus Foliaceus · Bullous Pemphigoid·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Bullous pemphigoid"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Bullous pemphigoid"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 36 interventional · 20 observational · 1 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T14:57:40.486Z
